Advantages of Concurrently Investigating Gene Therapies in Dogs and Humans

Video

Dan Oliver, cofounder and chief executive officer, Rejuvenate Bio, discussed the advantages of developing gene therapies for both dogs and humans.

“From a perspective of gene expression, there's nothing to keep your expression profiles the same once you pass the age when you would typically procreate... there's no evolutionary pressure to keep things regulated. We're hoping that with the tools available today, we can piece something together to effectively reverse events that have occurred over your lifetime.”

Rejuvenate Bio is focused on treating age-related diseases, with an ultimate goal of reversing aging. To this end, they are targeting 3 genes associated with longevity: FGF21, αKlotho, and TGFβ1 in both dogs and humans and developing gene therapies in both populations.

A single dose of Rejuvenate’s gene therapies were able to treat, and in some cases even reverse, a set of age-related diseases in mouse models, including obesity, type 2 diabetes, heart failure, and renal failure.

GeneTherapyLive spoke with Dan Oliver, cofounder and chief executive officer, Rejuvenate Bio, to learn more about the advantages of investigating the same gene therapies in both dogs and humans in manufacturing and data collection. He also discussed the company’s future plans and research to further their ultimate goal of reversing aging.

REFERENCE
Davidsohn N, Pezone M, Vernet A, et al. A single combination gene therapy treats multiple age-related diseases. Proc. Natl. Acad. Sci. USA. Nov 2019, 116 (47) 23505-23511. doi: 10.1073/pnas.1910073116

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.